GSK and Laboratorios Phoenix - Top 5 Emerging Market Deals

Who: GlaxoSmithKline
With: Laboratorios Phoenix
Where: Argentina

Deal Size: $253 million

Details: Earlier this year GlaxoSmithKline CEO Andrew Witty declared his company's intentions to grow beyond 'white pills and western markets.' The drugmaker has certainly done that, snapping up emerging market drug companies around the globe. It's biggest acquisition in the last 12 months was Argentinian company Laboratorios Phoenix. The drugmaker boasts a pipeline of branded generic pharmaceutical products covering therapeutic areas including cardiovascular, gastroenterology, metabolic and urology, as well as a manufacturing facility near Buenos Aires and an established primary care sales force.

According to IMS Argentina is the eighth largest emerging market, valued at $3 billion and growing at a rate of 22 percent annually. Phoenix reported sales of approximately $110 million in 2009 and it is currently ranked number eight in the Argentine pharmaceutical market. Prior to the acquisition GSK was in 11th place in Argentina; combined, the two companies are the third largest pharma company in the country.

GSK and Laboratorios Phoenix - Top 5 Emerging Market Deals

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.